Endotoxin: Possible roles in initiation and development of atherosclerosis

Journal of Laboratory and Clinical Medicine

Volumn 128, Issue 5, 1996, Pages 452-460

  Liao, Wei ^a,b,c  

^a NOVUM   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c CNT   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0030283073     PISSN: 00222143     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-2143(96)90042-6     Document Type: Review

References (101)

1. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993;362:801-9.
2. Ulevitch RJ, Tobias PS. Receptor-dependent mechanisms of cell stimulation by bacterial endotoxin. Ann Rev Immunol 1995;13:437-57.
3. Liao W, Florén CH. Hyperlipidemic response to endotoxin. A part of the host defence mechanism. Scand J Infect Dis 1993;25:675-82.
4. Pugin J, Ulevitch RJ, Tobias PS. Tumor necrosis factor-alpha and interleukin-1 beta mediate human endothelial cell activation in blood at low endotoxin concentrations. J Inflammation 1995;45:49-55.
5. Harlan JM, Harker LA, Reidy MA, Gajdusek CM, Schwartz SM, Striker GE. Lipopolysaccharide-mediated bovine endothelial cell injury in vitro. Lab Invest 1983;48:269-74.
6. Arditi M, Zhou J, Dorio R, Rong GW, Goyert SM, Kim KS. Endotoxin-mediated endothelial cell injury and activation: role of soluble CD14. Infect Immun 1993;61:3149-56.
7. Hailman E, Lichenstein HS, Wurfel MM, Miller DS, Johnson DA, Kelley M, et al. Lipopolysaccharide (LPS)-binding protein accelerates the binding of LPS to CD14. J Exp Med 1994;179:269-77.
8. Tobias PS, Soldau K, Gegner JA, Mintz D, Ulevitch RJ. Lipopolysaccharide binding protein-mediated complexation of lipopolysaccharide with soluble CD14. J Biol Chem 1995; 270:10482-8.
9. Yu B, Wright SD. Catalytic properties of lipopolysaccharide (LPS) binding protein - transfer of LPS to soluble CD14. J Biol Chem 1996;271:4100-5.
10. Frey EA, Miller DS, Jahr TG, Sundan A, Bazil V, Espevik T, et al. Soluble CD14 participates in the response of cells to lipopolysaccharide. J Exp Med 1992;176:1665-71.
11. Pugin J, Schurer-Maly CC, Leturcq D, Moriarty A, Ulevitch RJ, Tobias PS. Lipopolysaccharide activation of human endothelial and epithelial cells is mediated by lipopolysaccharide-binding protein and soluble CD14. Proc Natl Acad Sci USA 1993;90:2744-8.
12. Sharma SA, Olchowy TW, Yang Z, Breider MA. Tumor necrosis factor alpha and interleukin 1 alpha enhance lipopolysaccharide-mediated bovine endothelial cell injury. J Leukocyte Biol 1992;51:579-85.
13. Magnuson DK, Maier RV, Pohlman TH. Protein kinase C: a potential pathway of endothelial cell activation by endotoxin, tumor necrosis factor, and interleukin-1. Surgery 1989;106:216-22.
14. Wurfel MM, Kunitake ST, Lichenstein H, Kane JP, Wright SD. Lipopolysaccharide (LPS)-binding protein is carried on lipoproteins and acts as a cofactor in the neutralization of LPS. J Exp Med 1994;180:1025-35.
15. Wurfel MM, Hailman E, Wright SD. Soluble CD14 acts as a shuttle in the neutralization of lipopolysaccharide (LPS) by LPS-binding protein and reconstituted high density lipoprotein. J Exp Med 1995;181:1743-54.
16. Ulevitch RJ, Johnston AR, Weinstein DB. New function for high density lipoproteins. Their participation in intravascular reactions of bacterial lipopolysaccharides. J Clin Invest 1979;64:1516-24.
17. Lynn WA, Liu Y, Golenbock DT. Neither CD14 nor serum is absolutely necessary for activation of mononuclear phagocytes by bacterial lipopolysaccharide. Infect Immun 1993;61: 4452-61.
18. Haziot A, Ferrero E, Kontgen F, Hijiya N, Yamamoto S, Silver J, et al. Resistance to endotoxin shock and reduced dissemination of gram-negative bacteria in CD14-deficient mice. Immunity 1996;4:407-14.
19. Doherty DE, Zagarella L, Henson PM, Worthen GS. Lipopolysaccharide stimulates monocyte adherence by effects on both the monocyte and the endothelial cell. J Immunol 1989;143:3673-9.
20. Albelda SM, Smith CW, Ward PA. Adhesion molecules and inflammatory injury. FASEB J 1994;8:504-12.
21. Pober JS, Gimbrone MJ, Lapierre LA, Mendrick DL, Fiers W, Rothlein R, et al. Overlapping patterns of activation of human endothelial cells by interleukin 1, tumor necrosis factor, and immune interferon. J Immunol 1986;137:1893-6.
22. Bevilacqua MP, Pober JS, Mendrick DL, Cotran RS, Gimbrone MJ. Identification of an inducible endothelial-leukocyte adhesion molecule. Proc Natl Acad Sci USA 1987;84: 9238-42.
23. Bevilacqua MP, Stengelin S, Gimbrone MJ, Seed B. Endothelial leukocyte adhesion molecule 1: an inducible receptor for neutrophils related to complement regulatory proteins and lectins. Science 1989;243:1160-5.
24. Montgomery KF, Osborn L, Hession C, Tizard R, Goff D, Vassallo C, et al. Activation of endothelial-leukocyte adhesion molecule 1 (ELAM-1) gene transcription. Proc Natl Acad Sci USA 1991;88:6523-7.
25. Dustin ML, Springer TA. Lymphocyte function-associated antigen-1 (LFA-1) interaction with intercellular adhesion molecule-1 (ICAM-1) is one of at least three mechanisms for lymphocyte adhesion to cultured endothelial cells. J Cell Biol 1988;107:321-31.
26. Carlos TM, Schwartz BR, Kovach NL, Yee E, Rosa M, Osborn L, et al. Vascular cell adhesion molecule-1 mediates lymphocyte adherence to cytokine-activated cultured human endothelial cells. Blood 1990;76:965-70.
27. Masinovsky B, Urdal D, Gallatin WM. IL-4 acts synergistically with IL-1 beta to promote lymphocyte adhesion to microvascular endothelium by induction of vascular cell adhesion molecule-1. J Immunol 1990;145:2886-95.
28. Munro JM, Pober JS, Cotran RS. Tumor necrosis factor and interferon-gamma induce distinct patterns of endothelial activation and associated leukocyte accumulation in skin of Papio anubis. Am J Pathol 1989;135:121-33.
29. Munro JM, Pober JS, Cotran RS. Recruitment of neutrophils in the local endotoxin response: association with de novo endothelial expression of endothelial leukocyte adhesion molecule-1. Lab Invest 1991;64:295-9.
30. Liao W, Florén CH. Endotoxin, cytokines, and hyperlipidemia. Scand J Gastroenterol 1993;28:97-103.
31. Hardardottir I, Grunfeld C, Feingold KR. Effects of endotoxin and cytokines on lipid metabolism. Curr Opin Lipidol 1994;5:207-15.
32. Liao W, Rudling M, Angelin B. Endotoxin suppresses rat hepatic low density lipoprotein receptor expression. Biochem J 1996;313:873-8.
33. Harada K, Shimano H, Kawakami M, Ishibashi S, Gotoda T, Mori N, et al. Effect of tumor necrosis factor/cachectin on the activity of the low density lipoprotein receptor on human skin fibroblasts. Biochem Biophys Res Commun 1990;172:1022-7.
34. Grove RI, Mazzucco C, Allegretto N, Kiener PA, Spitalny G, Radka SF, et al. Macrophage-derived factors increase low density lipoprotein uptake and receptor number in cultured human liver cells. J Lipid Res 1991;32:1889-97.
35. Hamanaka R, Kohno K, Seguchi T, Okamura K, Morimoto A, Ono M, et al. Induction of low density lipoprotein receptor and a transcription factor SP-1 by tumor necrosis factor in human microvascular endothelial cells. J Biol Chem 1992;267:13160-5.
36. Liao W, Florén CH. Tumor necrosis factor up-regulates expression of low-density lipoprotein receptors on HepG2 cells. Hepatology 1993;17:898-907.
37. Stopeck AT, Nicholson AC, Mancini FP, Hajjar DP. Cytokine regulation of low density lipoprotein receptor gene transcription in HepG2 cells. J Biol Chem 1993;268:17489-94.
38. Liao W, Florén CH. Endotoxins inhibit endocytotic catabolism of low-density lipoproteins in Hep G2 cells. Hepatology 1992;16:224-31.
39. Liao W, Florén CH. Enhancement by lipoprotein-free plasma of the inhibitory effect of endotoxin on endocytotic catabolism of low density lipoproteins in Hep G2 cells. Eur J Biochem 1994;220:349-57.
40. Sakaguchi S. Metabolic disorders of serum lipoproteins in endotoxin-poisoned mice: the role of high density lipoprotein (HDL) and triglyceride-rich lipoproteins. Microbiol Immunol 1982;26:1017-34.
41. Sakaguchi S, Kanda N, Hsu CC, Sakaguchi O. Lipid peroxide formation and membrane damage in endotoxin-poisoned mice. Microbiol Immunol 1981;25:229-44.
42. Bautista AP, Spitzer JJ. Superoxide anion generation by in situ perfused rat liver: effect of in vivo endotoxin. Am J Physiol 1990;259:G907-12.
43. Bautista AP, Meszaros K, Bojta J, Spitzer JJ. Superoxide anion generation in the liver during the early stage of endotoxemia in rats. J Leukoc Biol 1990;48:123-8.
44. Schulze OK, Bakker AC, Vanhaesebroeck B, Beyaert R, Jacob WA, Fiers W. Cytotoxic activity of tumor necrosis factor is mediated by early damage of mitochondrial functions. Evidence for the involvement of mitochondrial radical generation. J Biol Chem 1992;267:5317-23.
45. Bautista AP, Schuler A, Spolarics Z, Spitzer JJ. Tumor necrosis factor-alpha stimulates superoxide anion generation by perfused rat liver and Kupffer cells. Am J Physiol 1991;261:G891-5.
46. Maziere C, Auclair M, Maziere JC. Tumor necrosis factor enhances low density lipoprotein oxidative modification by monocytes and endothelial cells. FEBS Lett 1994;338:43-6.
47. Morel DW, DiCorleto PE, Chisolm GM. Modulation of endotoxin-induced endothelial cell toxicity by low density lipoprotein. Lab Invest 1986;55:419-26.
48. Van Lenten BJ, Fogelman AM, Seager J, Ribi E, Haberland ME, Edwards PA. Bacterial endotoxin selectively prevents the expression of scavenger-receptor activity on human monocyte-macrophages. J Immunol 1985;134:3718-21.
49. Van Lenten BJ, Fogelman AM. Lipopolysaccharide-induced inhibition of scavenger receptor expression in human monocyte-macrophages is mediated through tumor necrosis factor-alpha. J Immunol 1992;148:112-6.
50. Geng YJ, Hansson GK. Interferon-gamma inhibits scavenger receptor expression and foam cell formation in human monocyte-derived macrophages. J Clin Invest 1992;89:1322-30.
51. Lopes-Virella MF, Klein RL, Stevenson HC. Low density lipoprotein metabolism in human macrophages stimulated with microbial or microbial-related products. Arteriosclerosis 1987;7:176-84.
52. Oiknine J, Aviram M. Increased susceptibility to activation and increased uptake of low density lipoprotein by cholesterol-loaded macrophages. Arterioscler Thromb 1992;12: 745-53.
53. Aviram M, Oiknine J. Involvement of second messengers in lipopolysaccharide stimulation of low density lipoprotein uptake by macrophages. Isr J Med Sci 1994;30:503-6.
54. Funk JL, Feingold KR, Moser AH, Grunfeld C. Lipopolysaccharide stimulation of RAW 264.7 macrophages induces lipid accumulation and foam cell formation. Atherosclerosis 1993;98:67-82.
55. Martinet Y, Bitterman PB, Mornex JF, Grotendorst GR, Martin GR, Crystal RG. Activated human monocytes express the c-sis proto-oncogene and release a mediator showing PDGF-like activity. Nature 1986;319:158-60.
56. Albelda SM, Elias JA, Levine EM, Kern JA. Endotoxin stimulates platelet-derived growth factor production from cultured human pulmonary endothelial cells. Am J Physiol 1989;257:L65-70.
57. Malden LT, Chait A, Raines EW, Ross R. The influence of oxidatively modified low density lipoproteins on expression of platelet-derived growth factor by human monocyte-derived macrophages. J Biol Chem 1991;266:13901-7.
58. Prescott MF, McBride CK, Court M. Development of intimal lesions after leukocyte migration into the vascular wall. Am J Pathol 1989;135:835-46.
59. Singh TM, Kadowaki MH, Glagov S, Zarins CK. Role of fibrinopeptide B in early atherosclerotic lesion formation. Am J Surg 1990;160:156-9.
60. Ito A, Shimokawa H, Kadokami T, Fukumoto Y, Owada MK, Shiraishi T, et al. Tyrosine kinase inhibitor suppresses coronary arteriosclerotic changes and vasospastic responses induced by chronic treatment with interleukin-1β in pigs in vivo. J Clin Invest 1995;96:1288-94.
61. Morrison DC, Ulevitch RJ. The effects of bacterial endotoxins on host mediation systems. A review. Am J Pathol 1978;93:526-617.
62. Colucci M, Balconi G, Lorenzet R, Pietra A, Locati D, Donati MB, et al. Cultured human endothelial cells generate tissue factor in response to endotoxin. J Clin Invest 1983;71:1893-6.
63. Bevilacqua MP, Pober JS, Majeau GR, Cotran RS, Gimbrone MJ. Interleukin 1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells. J Exp Med 1984;160:618-23.
64. Bevilacqua MP, Pober JS, Majeau GR, Fiers W, Cotran RS, Gimbrone MJ. Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin 1. Proc Natl Acad Sci USA 1986;83:4533-7.
65. Nawroth PP, Handley DA, Esmon CT, Stern DM. Interleukin 1 induces endothelial cell procoagulant while suppressing cell-surface anticoagulant activity. Proc Natl Acad Sci USA 1986;83:3460-4.
66. Conkling PR, Greenberg CS, Weinberg JB. Tumor necrosis factor induces tissue factor-like activity in human leukemia cell line U937 and peripheral blood monocytes. Blood 1988; 72:128-33.
67. Scheibenbogen C, Moser H, Krause S, Andreesen R. Interferon-gamma-induced expression of tissue factor activity during human monocyte to macrophage maturation. Haemostasis 1992;22:173-8.
68. Ternisien C, Ramani M, Ollivier V, Khechai F, Vu T, Hakim J, et al. Endotoxin-induced tissue factor in human monocytes is dependent upon protein kinase C activation. Thromb Haemost 1993;70:800-6.
69. Herbert JM, Savi P, Laplace MC, Dumas A, Dol F. Chelerythrine, a selective protein kinase C inhibitor, counteracts pyrogen-induced expression of tissue factor without effect on thrombomodulin down-regulation in endothelial cells. Thromb Res 1993;71:487-93.
70. Ameri A, Kuppuswamy MN, Basu S, Bajaj SP. Expression of tissue factor pathway inhibitor by cultured endothelial cells in response to inflammatory mediators. Blood 1992;79: 3219-26.
71. McGee MP, Foster S, Wang X. Simultaneous expression of tissue factor and tissue factor pathway inhibitor by human monocytes. A potential mechanism for localized control of blood coagulation. J Exp Med 1994;179:1847-54.
72. Scarpati EM, Sadler JE. Regulation of endothelial cell coagulant properties. Modulation of tissue factor, plasminogen activator inhibitors, and thrombomodulin by phorbol 12-myristate 13-acetate and tumor necrosis factor. J Biol Chem 1989;264:20705-13.
73. Moore KL, Andreoli SP, Esmon NL, Esmon CT, Bang NU. Endotoxin enhances tissue factor and suppresses thrombomodulin expression of human vascular endothelium in vitro. J Clin Invest 1987;79:124-30.
74. Nawroth PP, Stern DM. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med 1986;163:740-5.
75. Hanss M, Collen D. Secretion of tissue-type plasminogen activator and plasminogen activator inhibitor by cultured human endothelial cells: modulation by thrombin, endotoxin, and histamine. J Lab Clin Med 1987;109:97-104.
76. Crutchley DJ, Conanan LB, Ryan US. Endotoxin-induced secretion of an active plasminogen activator inhibitor from bovine pulmonary arterial and aortic endothelial cells. Biochem Biophys Res Commun 1987;148:1346-53.
77. Medina R, Socher SH, Han JH, Friedman PA. Interleukin-1, endotoxin or tumor necrosis factor/cachectin enhance the level of plasminogen activator inhibitor messenger RNA in bovine aortic endothelial cells. Thromb Res 1989;54:41-52.
78. Bevilacqua MP, Schleef RR, Gimbrone MJ, Loskutoff DJ. Regulation of the fibrinolytic system of cultured human vascular endothelium by interleukin 1. J Clin Invest 1986; 78:587-91.
79. Colucci M, Paramo JA, Collen D. Generation in plasma of a fast-acting inhibitor of plasminogen activator in response to endotoxin stimulation. J Clin Invest 1985;75: 818-24.
80. Quax PH, van den Hoogen CM, Verheijen JH, Padro T, Zeheb R, Gelehrter TD, et al. Endotoxin induction of plasminogen activator and plasminogen activator inhibitor type 1 mRNA in rat tissues in vivo. J Biol Chem 1990;265: 15560-3.
81. Suffredini AF, Harpel PC, Parrillo JE. Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects. N Engl J Med 1989;320:1165-72.
82. Reidy MA, Bowyer DE. Scanning electron microscopy: morphology of aortic endothelium following injury by endotoxin and during subsequent repair. Atherosclerosis 1977; 26:319-28.
83. Reidy MA, Bowyer DE. Distortion of endothelial repair. The effect of hypercholesterolaemia on regeneration of aortic endothelium following injury by endotoxin. A scanning electron microscope study. Atherosclerosis 1978;29:459-66.
84. Grayston JT, Kuo CC, Campbell LA, Benditt EP. Chlamydia pneumoniae, strain TWAR and atherosclerosis. Eur Heart J 1993;14(suppl K):66-71.
85. Ingalls RR, Rice PA, Qureshi N, Takayama K, Lin JS, Golenbock DT. The inflammatory cytokine response to chlamydia trachomatis infection is endotoxin mediated. Infect Immun 1995;63:3125-30.
86. Redl H, Bahrami S, Schlag G, Traber DL. Clinical detection of LPS and animal models of endotoxemia. Immunobiology 1993;187:330-45.
87. Kritchevsky D. Laboratory models for atherosclerosis. Adv Drug Res 1974;9:41-53.
88. Armstrong ML, Heistad DD. Animal models of atherosclerosis. Atherosclerosis 1990;85:15-23.
89. Paigen B, Morrow A, Brandon C, Mitchell D, Holmes P. Variation in susceptibility to atherosclerosis among inbred strains of mice. Atherosclerosis 1985;57:65-73.
90. Paigen B, Holmes PA, Mitchell D, Albee D. Comparison of atherosclerotic lesions and HDL-lipid levels in male, female, and testosterone-treated female mice from strains C57BL/6, BALB/c, and C3H. Atherosclerosis 1987;64:215-21.
91. Paigen B, Ishida BY, Verstuyft J, Winters RB, Albee D. Atherosclerosis susceptibility differences among progenitors of recombinant inbred strains of mice. Arteriosclerosis 1990;10:316-23.
92. Watson J, Riblet R, Taylor BA. The response of recombinant inbred strains of mice to bacterial lipopolysaccharides. J Immunol 1977;118:2088-93.
93. Watson J, Kelly K, Largen M, Taylor BA. The genetic mapping of a defective LPS response gene in C3H/HeJ mice. J Immunol 1978;120:422-4.
94. Paigen B, Albee D, Holmes PA, Mitchell D. Genetic analysis of murine strains C57BL/6J and C3H/HeJ to confirm the map position of Ath-1, a gene determining atherosclerosis susceptibility. Biochem Genet 1987;25:501-11.
95. Kerttula Y, Vaara M, Pyhala L, Sariola H, Kostiainen E, Huttunen JK. Effect of bacterial lipopolysaccharide on serum lipids and on the development of aortic atherosclerosis in rabbits. Atherosclerosis 1986;59:307-12.
96. Pesonen E, Kaprio E, Rapola J, Soveri T, Viikari J, Savilahti E, et al. Effect of repeated endotoxin treatment and hypercholesterolemia on preatherosclerotic lesions in weaned pigs. Part 1. Scanning and transmission electron microscopic study. Atherosclerosis 1987;65:89-98.
97. Yla-Herttuala S, Pesonen E, Kaprio E, Rapola J, Soveri T, Viikari J, et al. Effect of repeated endotoxin treatment and hypercholesterolemia on preatherosclerotic lesions in weaned pigs. Part II. Lipid and glycosaminoglycan analysis of intima and inner media. Atherosclerosis 1988;72: 173-81.
98. Gupta M, Parker JL, Adams HR, Myers PR. Chronic endotoxemia suppresses atherogenesis in rabbit aorta [abstract]. Circulation 1993;88:I,522.
99. Hermus AR, Sweep CG, Demacker PN, van der Meer MJ, Kloppenborg PW, van der Meer JW. Continuous infusion of interleukin-1 beta in rats induces a profound fall in plasma levels of cholesterol and triglycerides. Arterioscler Thromb 1992;12:1036-43.
100. Navab M, Hough GP, van Lenten BJ, Berliner JA, Fogelman AM. Low density lipoproteins transfer bacterial lipopolysaccharides across endothelial monolayers in a biologically active form. J Clin Invest 1988;81:601-5.
101. Breslow JL. Mouse models of atherosclerosis. Science 1996; 272:685-8.